AI-ACCELERATED DRUG DISCOVERY
Receptor.AI to Contribute AI-Driven Peptide Design Expertise and Join Leadership Boards in Global Initiative Advancing Next-Gen Peptide Therapeutics
Boston, MA – April 1, 2025 – Receptor.AI, a preclinical TechBio company advancing the AI drug discovery ecosystem, today announced its integration into the Peptide Drug Hunting Consortium (PDHC). The consortium is a global network that connects academia, biotech, pharma, and investors to advance next-generation peptide therapeutics through collaboration, education, and mentorship.
Receptor.AI employs an AI-guided platform to design and optimize both linear and cyclic peptides that address challenging targets, including “undruggable” protein-protein interactions. This capability, combined with strategic collaborations with leading pharmaceutical companies, has established the company as a key player in peptide therapeutic design.
In conjunction with joining PDHC, Receptor.AI’s leadership is assuming significant roles within the consortium. Dr. Alan Nafiiev, CEO and Co-Founder of Receptor.AI, has been appointed to the Entrepreneurial Business Network (EBN) on the business board, and Dr. Semen Yesylevskyy, CSO and Co-Founder of Receptor.AI, has joined the Entrepreneurial Advisory Board (EAB) on the scientific side.
"After decades in drug discovery and with a deep passion for peptide modalities, I am pleased to see the vision of the Peptide Drug Hunting Consortium transform into a reality,” said Dr. Tomi K. Sawyer, Founding President of PDHC. “This network is poised to drive breakthrough medicines through entrepreneurial science and collaboration."
"We are honored to join PDHC and look forward to contributing our expertise in AI-driven peptide design to advance next-generation therapeutics," said Dr. Alan Nafiiev, CEO of Receptor.AI.
Receptor.AI is a preclinical TechBio company specializing in generative AI for drug discovery. Receptor.AI has developed a robust, validated AI-driven ecosystem tailored to address complex protein targets, comprising three core platforms:
Built on extensive experience and over 40 successful joint discovery projects, Receptor.AI’s multiplatform ecosystem empowers researchers to design small molecules, peptides, and induced proximity agents with unprecedented speed and accuracy. By focusing on validated, modular workflows that integrate seamlessly into existing R&D processes, Receptor.AI has become a trusted partner to big pharma companies and academic institutions worldwide. For further information, please visit the company’s website at receptor.ai.
The Peptide Drug Hunting Consortium (PDHC) is a global network dedicated to advancing peptide drug discovery. By connecting academia, biotech companies, pharmaceutical firms, contract research organizations, and investors, PDHC fosters collaboration and supports innovative initiatives in peptide therapeutics. The consortium promotes education, mentorship, and resource sharing to accelerate the development and clinical translation of next-generation peptide drugs.
Receptor.AI
Tetiana Skakun, Marketing Specialist
tetiana.skakun@receptor.ai
